Cited 20 times in
Lysyl-tRNA Synthetase (KRS) Expression in Gastric Carcinoma and Tumor-Associated Inflammation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤선옥 | - |
dc.contributor.author | 홍순원 | - |
dc.date.accessioned | 2015-01-06T16:45:58Z | - |
dc.date.available | 2015-01-06T16:45:58Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98726 | - |
dc.description.abstract | BACKGROUND: Lysyl-tRNA synthetase (KRS) is an aminoacyl-tRNA synthetase (ARS) that is essential for protein synthesis during ligation of specific amino acids to their cognate tRNAs. Aberrant expression of ARSs is associated with various human cancers. METHODS: Using immunohistochemical detection, the present study analyzed the clinical relevance of KRS expression in tumor cells and tumor-associated inflammatory cells (TAI) in 457 patients who underwent curative radical surgery and standard adjuvant therapy and who were observed on long-term follow-up. RESULTS: High expression of KRS in tumor cells (tumor-KRS(+)) was noted in 43.3 % (198 of 457) of cases. High expression of KRS in tumor-associated inflammatory cells (TAI-KRS(+)) including macrophages/monocytes, CD4-positive T cells, and/or neutrophils was observed in 37.2 % (170 of 457) of cases. Status of KRS in the tumor and TAI revealed an association with the known clinicopathological parameters for prognosis of gastric cancer. Tumor-KRS(+) status correlated to shorter overall survival, especially in stage III to IV cancers (P = 0.003), while TAI-KRS(+) status correlated significantly to longer overall survival in gastric cancer (P = 0.049). Cases with tumor-KRS(+) and TAI-KRS(-) status showed significantly reduced survival rates compared to those of other cases (P = 0.010), and status of tumor-KRS(+) and TAI-KRS(-) was revealed as an independently poor prognostic factor of overall survival (P = 0.001). CONCLUSIONS: KRS-related inflammation can be identified in a subset of gastric cancer. This may be a possible mechanism of immune surveillance against tumor progression. In addition, expression status of KRS in tumor and TAI may be an independent prognostic marker for gastric cancer patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 2020~2027 | - |
dc.relation.isPartOf | ANNALS OF SURGICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | CD4-Positive T-Lymphocytes/chemistry | - |
dc.subject.MESH | Carcinoma/chemistry* | - |
dc.subject.MESH | Carcinoma/pathology* | - |
dc.subject.MESH | Carcinoma/therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Inflammation/pathology* | - |
dc.subject.MESH | Ki-67 Antigen/analysis | - |
dc.subject.MESH | Lysine-tRNA Ligase/analysis* | - |
dc.subject.MESH | Macrophages/chemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Monocytes/chemistry | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Neutrophils/chemistry | - |
dc.subject.MESH | Stomach Neoplasms/chemistry* | - |
dc.subject.MESH | Stomach Neoplasms/pathology* | - |
dc.subject.MESH | Stomach Neoplasms/therapy | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/analysis | - |
dc.title | Lysyl-tRNA Synthetase (KRS) Expression in Gastric Carcinoma and Tumor-Associated Inflammation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Baek-hui Kim | - |
dc.contributor.googleauthor | Woon Yong Jung | - |
dc.contributor.googleauthor | Hyunjoo Lee | - |
dc.contributor.googleauthor | Youngran Kang | - |
dc.contributor.googleauthor | You-Jin Jang | - |
dc.contributor.googleauthor | Soon Won Hong | - |
dc.contributor.googleauthor | Hyeong-jae Jeong | - |
dc.contributor.googleauthor | Sun Och Yoon | - |
dc.identifier.doi | 10.1245/s10434-014-3522-z | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02566 | - |
dc.contributor.localId | A04411 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 24558064 | - |
dc.identifier.url | http://link.springer.com/article/10.1245%2Fs10434-014-3522-z | - |
dc.subject.keyword | Gastric Cancer | - |
dc.subject.keyword | Expression Status | - |
dc.subject.keyword | Digital Slide | - |
dc.subject.keyword | Independent Poor Prognostic Factor | - |
dc.subject.keyword | Standard Adjuvant Therapy | - |
dc.contributor.alternativeName | Yoon, Sun Och | - |
dc.contributor.alternativeName | Hong, Soon Won | - |
dc.contributor.affiliatedAuthor | Yoon, Sun Och | - |
dc.contributor.affiliatedAuthor | Hong, Soon Won | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 21 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 2020 | - |
dc.citation.endPage | 2027 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL ONCOLOGY, Vol.21(6) : 2020-2027, 2014 | - |
dc.identifier.rimsid | 38566 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.